<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3560">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760132</url>
  </required_header>
  <id_info>
    <org_study_id>ENFORCE</org_study_id>
    <nct_id>NCT04760132</nct_id>
  </id_info>
  <brief_title>National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)</brief_title>
  <acronym>ENFORCE</acronym>
  <official_title>National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jens D Lundgren, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of the Interior and Health, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      National cohort study of effectiveness and safety of SARS-CoV-2 vaccines (ENFORCE is an&#xD;
      equivalence trial to evaluate the effectiveness and safety of multiple new SARS-CoV-2&#xD;
      vaccines approved for use in the EU, and which are being offered at participating units.&#xD;
&#xD;
      The design is an open-labelled, non-randomised, parallel group, phase IV study with&#xD;
      historical controls.&#xD;
&#xD;
      A sub-study will be embedded within this master protocol addressing basic and translational&#xD;
      research questions requiring additional sampling of biological material (under separate&#xD;
      participant informed consent).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First phase will enrol 10,000 persons initiating vaccination (assuming 4 vaccines). If more&#xD;
      vaccines become available additional 2,500 persons per vaccine will be included. Subsequent&#xD;
      phases with larger sections of the population included may be implemented.&#xD;
&#xD;
      Participants will have 6 study visits and be followed for 2 years after the first&#xD;
      vaccination, which offers the participants an extra close follow up on vaccine effectiveness.&#xD;
      Safety data will be collected at study visits until 3 months after the first vaccination.&#xD;
      Research samples will be collected at each study visit during the two year follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The design is an open-labelled, non-randomised, parallel group, phase IV study with historical controls.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the effectiveness of citizens being vaccinated with one of the SARS-CoV-2 vaccines</measure>
    <time_frame>The change from Base-line in MPNAT measured via profiling of antibodies against SARS-CoV-2 Spike epitopes at 24 month</time_frame>
    <description>Primary outcome is the minimal protective neutralising antibody titre (MPNAT); i.e. the minimum level of neutralising antibodies sufficient to protect the person from becoming infected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of breakthrough infections in the 24 months period will be used to compare the effectiveness between the vaccines</measure>
    <time_frame>The change from first vaccination until 24 month</time_frame>
    <description>Number of confirmed positive SARS-CoV-2 tests reported via the national testing system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety of the vaccines will be compared between groups</measure>
    <time_frame>From first vaccine until Day 90</time_frame>
    <description>Reports of participants with local and systemic reactions to the vaccination will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of any Adverse Event from the vaccines will be compared between groups</measure>
    <time_frame>From first vaccine until Day 90</time_frame>
    <description>Reports of participants with grade 3 and 4 Adverse Events and any Serious Adverse will be collected</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Vaccine A - COMIRNATY COVID-19 vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COMIRNATY (COVID-19, mRNA Vaccine) by BioNTech Manufacturing GmbH Marketing Authorisation EU/1/20/1528</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine B - Moderna COVID-19 vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COVID-19 Vaccine Moderna dispersion for injection (COVID-19, mRNA Vaccine) by MODERNA BIOTECH SPAIN S.L.&#xD;
Marketing Authorisation EU/1/20/1507/001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine C - Astra-Zeneca COVID-19 vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COVID-19 Vaccine AstraZeneca suspension for injection (ChAdOx1-S [recombinant]) by AstraZeneca AB Marketing Authorisation EU/1/21/1529/001 and /002</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COMIRNATY - BioNTech Manufacturing GmbH</intervention_name>
    <description>Vaccination as part of the the Danish national government programme</description>
    <arm_group_label>Vaccine A - COMIRNATY COVID-19 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH</intervention_name>
    <description>Vaccination as part of the the Danish national government programme</description>
    <arm_group_label>Vaccine B - Moderna COVID-19 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Vaccine AstraZeneca suspension for injection</intervention_name>
    <description>Vaccination as part of the the Danish national government programme</description>
    <arm_group_label>Vaccine C - Astra-Zeneca COVID-19 vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained before any trial related procedures are performed&#xD;
&#xD;
          2. Male or female eligible for SARS-CoV-2 immunization (as defined by SST in the national&#xD;
             vaccination plan)&#xD;
&#xD;
          3. The subject must be willing and able to comply with trial protocol (re-visits and&#xD;
             biological samples)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male and female under the age of 18&#xD;
&#xD;
          2. Any subgroup of individuals for which the vaccines are contraindicated&#xD;
&#xD;
          3. Previous SARS-CoV-2 vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Lundgren, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorthe Raben</last_name>
    <phone>+45 3545 5757</phone>
    <email>dorthe.raben@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte B Nielsen</last_name>
    <phone>+45 3545 5757</phone>
    <email>charlotte.bjernved.nielsen.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus Universitetshospital, Skejby</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Lars Østergaard, Professor</last_name>
      <phone>+45 7845 2800</phone>
      <email>Larsoest@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Nina B Stærke, MD</last_name>
      <email>NINASE@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aalborg Universityhospital Syd</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Henrik Nielsen, MD</last_name>
      <phone>+45 9766 3900</phone>
      <email>henrik.nielsen@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas L Benfield, Professor</last_name>
      <phone>+45 3862 2302</phone>
      <email>thomas.lars.benfield@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universityhospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Isik S Johansen, Professor</last_name>
      <phone>45 6541 2652</phone>
      <email>isik.somuncu.johansen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sjællandsuniversitetshospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Lothar Wiese, MD</last_name>
      <phone>+45 4532 3200</phone>
      <email>low@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Jens D Lundgren, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

